Levetiracetam (Keppra)


Excerpt from Cafer's Mood Stabilizers and Antiepileptics

 Levetiracetam (KEPPRA) 

 Pronunciation: LEE ve tye RA se tam / KEP ruh
“Levitate Keeper”
Levetiracetam (Keppra) mascot by Jason Cafer MD
Levetiracetam (Keppra) alternate mascot by Jason Cafer MD 
❖ Antiepileptic 
❖ Inhibitor of glutamate release		FDA approved for:
❖ Focal seizures (adjunct) 
❖ Juvenile myoclonic epilepsy (adjunct) 
❖ Bilateral tonic-clonic seizures (adjunct)		Used off label for: 
❖ Other types of seizures

 Levetiracetam entered the U.S. market in 2000 as an AED with a novel mechanism of action. It binds SV2A, a synaptic vesicle glycoprotein. This reduces the release of glutamate, the brain’s principal excitatory neurotransmitter, thereby preventing hypersynchronization of epileptiform burst firing.

 
Levetiracetam has become one of the most prescribed medications for the treatment of epilepsy. It is not prescribed by psychiatrists. Advantages of levetiracetam as an AED include efficacy for a broad-spectrum of seizure types, lack of cognitive impairment, and  lack of drug interactions. It can be started at an effective 500 mg BID dose on day one, which is also nice. Half-life is about 7 hours. 66% is excreted unchanged in the urine.

The most common side effects are dizziness, fatigue, and insomnia. The more troublesome problem with Keppra can be irritability and mood changes. This may occur to some degree in up to a third of patients taking the medicine (Dr. Robert Fisher, epilepsy.com). The array of psychiatric adverse effects may include depression, suicidal ideation, psychosis, hostility, and aggression.  If a patient on Keppra experiences behavioral disturbance, they can be switched to brivaracetam (Briviact), a similar AED with a lower incidence of mood disruption.

Dosing: A typical adult dose for levetiracetam is 500–1500 mg twice a day. Dr. Fisher usually starts with 250 mg BID x 1 wk, then 500 mg BID x 1 wk, then 1000 mg AM + 500 mg PM x 1 wk, then 1000 mg BID. This is slower than the package insert suggests. 

Dynamic interactions: 
❖ Sedation (minimal)		Keppra has no significant pharmacokinetic interactions by jason cafer mdKinetic interactions:
❖ None significant - “in a bubble”
Cafermed







































Comments











Post a Comment























Popular posts from this blog









Cenobamate (XCOPRI) visual mnemonics




















Image







Excerpt from  Cafer's Mood Stabilizers and Antiepileptics, available on Amazon Cenobamate (XCOPRI) “Cinnab on  Ex-co uple ” Pronunciation:  sen oh BAM ate / EX cop ree  ❖ Antiepileptic  ❖ GABA A  modulator  ❖ DEA Schedule V   FDA approved for:   ❖ Partial-onset seizures (adults)   Cenobamate (Xcopri) is the newest antiepileptic drug (AED) , released in 2020. There are some serious risks , side effects and kinetic drug/drug interactions.   Dosing is similar to lamotrigine (Lamictal), with a slow titration to a recommended dose  of 200 mg over 11 weeks . As with lamotrigine, maximum dose is 400 mg. The slow titration is necessary to avoid Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) , also known as multiorgan hypersensitivity. There were no cases of DRESS among over 1,000 patients with adherence to the slow titration schedule. Cenobamate shortens QT  interval and is contraindicated with Familial Short QT Syndrome. QTc interval under 300 is dangerous.   Dose-dependent








Read more










Pregabalin mascot & Black Friday Sale




















Image







Check out the Black Friday sale on Cafer's Psychopharmacology: Visualize to Memorize 270 Medication Mascots.  For a limited time, the paperback is $49.95  and the PDF version is $29.95  (regular price $89.95).  The PDF is formatted for ultra-rapid navigation with thousands of internal links. Included are medication mascots to assist you with memorization of trade name / generic name pairings. Here are excerpts from from 5-star Amazon reviews: ★★★★★ Love it I barely look at the pictures, honestly. I'm most impressed by the way the author explains everything through text, simply and efficiently. ★★★★★  GREAT PSYCH NO STUDENT EASY TO READ RESOURCE This breaks things down easily and is a great study resource for those needing something more concise and easier to read. ★★★★★  THIS BOOK helped me SO MUCH! First of all, I don’t write reviews but this book deserves it. I am in a CMHC graduate program where a class asked me to know most of the antipsychotics and antidepressants. It was 








Read more










Lumateperone (Caplyta)




















Image







Available on Amazon:  Cafer's Mood Stabilizers and Antiepileptic Drugs        Lumateperone (CAPLYTA) Pronunciation:  luma TEP er ohn / cap LIE ta  “’Lum inated  Cap lighter” Antipsychotics are represented  with spooky mascots. Year of US release: 2020  ❖ Antipsychotic (SGA) ❖ D2 antagonist - ⇩DA ❖ 5-HT2A antagonist - ⇧DA ❖ Glutamate modulator  FDA-approved for:  ❖ Schizophrenia  Lumateperone is a new antipsychotic that purportedly modulates glutamate  in addition to the usual SGA mechanism of blocking D2 and 5-HT2A receptors. However, the official prescribing information does not mention glutamate, suggesting the FDA saw insufficient evidence for lumateperone being a first-in-class novel antipsychotic. It appears to be equally effective as risperidone (Risperdal) with fewer side effects other than sedation (Citrome, 2016).  Lumateperone’s D2 receptor occupancy is lower than most other antipsychotics. This means extrapyramidal side effects are unlikely. The other antipsychotics with








Read more